Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies
{{output}}
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized hematologic oncology but remains largely ineffective against solid tumors, which evade immune attack through antigen heterogeneity, a suppressive tumor microenvironment (TME), and physical barri... ...
